Chemokines and anti-cancer immunotherapy: Anti-tumor effect of EBI1-ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC)

Anticancer Research

Volumn 20, Issue 6 A, 2000, Pages 4073-4080

  Nomura, T ^a   Hasegawa, H ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; Chemokines; Gene therapy

Indexed keywords

ALPHA CHEMOKINE; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CXCR4; EBI1 LIGAND CHEMOKINE; EOTAXIN; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 8; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CHEMOTAXIS; CONFERENCE PAPER; CONTROLLED STUDY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; CHEMOKINES, CC; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 0033637339     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (71)

1. Cancer vaccines
2. Advances in cancer immunotherapy
3. Tumor immunotherapy: Cytokines and antigen presentation
4. Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review
5. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
6. Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma: A phase II trial
7. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells
8. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer
9. Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
10. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: A phase IB study
11. Chemokines
12. Human chemokines: An update
13. Novel lymphocyte-specific CC chemokines and their receptors
14. Chemokines and leukocyte traffic
15. Chemokines and cell migration in secondary lymphoid organs
16. The role of chemokines in regulating cell migration during humoral immune responses
17. Properties of the novel proinflammatory supergene 'intercrine' cytokine family
18. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration
19. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice
20. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells
21. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth and susceptibility to IL-2 therapy of a murine melanoma
22. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells
23. Cytokine regulation of tumour-associated macrophages
24. A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice
25. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1alpha-expressing tumor: Linkage between inflammation and specific immunity
26. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity
27. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4
28. Hepatic arterial infusion of recombinant platelet factor-4 suppresses metastases to the lungs from tumors implanted into the livers of rabbits
29. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo
30. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation
31. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
32. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases
33. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo
34. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
35. Interleukin-8 suppresses the toxicity and antitumor effect of interleukin-2
36. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice
37. Genetic fusion of chemokines to a self-tumor antigen induces protective, T-cell dependent antitumor immunity
38. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: Perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor
39. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo
40. Inhibition of in vivo tumor growth by the beta chemokine, TCA3
41. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations
42. Combined chemokine and cytokine gene transfer enhances antitumor immunity
43. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models
44. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity
45. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13
46. Identification and characterization of a novel beta chemokine containing six conserved cysteines
47. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7
48. Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3alpha and MIP-3beta
49. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes
50. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7
51. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells
52. A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells
53. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells
54. Cutting edge: Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes
55. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7
56. Epstein-Barr virus-induced genes: First lymphocyte-specific G protein-coupled peptide receptors
57. + T cells
58. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
59. Cutting edge: Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties
60. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation
61. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells
62. A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4
63. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization
64. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
65. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
66. Dendritic cells and the control of immunity
67. Origin, maturation and antigen presenting function of dendritic cells
68. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity
69. Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design
70. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells
71. Evidence that granulocyte-macrophage colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers